PHS
HRTX icon

Pekin Hardy Strauss’s Heron Therapeutics HRTX Stock Holding History

Pekin Hardy Strauss’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.97K Sell
13,992
-2,000
-13% -$1.6K ﹤0.01% 511
2026
Q1 		$12.8K Hold
15,992
– – ﹤0.01% 477
2025
Q4 		$20.8K Buy
+15,992
New +$19.7K ﹤0.01% 453
2024
Q4 		– Sell
-15,170
Closed -$30.2K – 372
2024
Q3 		$30.2K Sell
15,170
-10,000
-40% -$23.9K ﹤0.01% 339
2024
Q2 		$88.1K Sell
25,170
-6,000
-19% -$18.4K 0.01% 316
2024
Q1 		$86.3K Sell
31,170
-5,300
-15% -$13.3K 0.01% 316
2023
Q4 		$62K Sell
36,470
-22,625
-38% -$24.9K 0.01% 297
2023
Q3 		$60.9K Sell
59,095
-47,050
-44% -$67K 0.01% 302
2023
Q2 		$123K Sell
106,145
-465,560
-81% -$830K 0.01% 295
2023
Q1 		$863K Sell
571,705
-150
-0% -$376 0.12% 154
2022
Q4 		$1.43M Sell
571,855
-71,260
-11% -$230K 0.2% 113
2022
Q3 		$2.71M Buy
643,115
+2,275
+0.4% +$8.9K 0.43% 65
2022
Q2 		$1.79M Buy
640,840
+42,575
+7% +$171K 0.25% 96
2022
Q1 		$3.42M Buy
598,265
+28,025
+5% +$205K 0.43% 60
2021
Q4 		$5.21M Buy
570,240
+126,855
+29% +$1.3M 0.7% 37
2021
Q3 		$4.74M Sell
443,385
-333,315
-43% -$4.06M 0.68% 35
2021
Q2 		$12.1M Buy
776,700
+255,895
+49% +$4.07M 1.68% 8
2021
Q1 		$8.44M Buy
520,805
+54,368
+12% +$969K 1.33% 18
2020
Q4 		$9.87M Sell
466,437
-128,476
-22% -$2.23M 1.71% 9
2020
Q3 		$8.82M Buy
594,913
+142
+0% +$2.22K 1.8% 9
2020
Q2 		$8.75M Buy
594,771
+6,039
+1% +$99.2K 1.93% 10
2020
Q1 		$6.91M Buy
588,732
+98,772
+20% +$1.86M 1.55% 15
2019
Q4 		$11.5M Buy
+489,960
New +$10.8M 1.89% 14

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Pekin Hardy Strauss's HRTX Position: Q2 2026 in Review

Pekin Hardy Strauss reduced its Heron Therapeutics (HRTX) stake by 13% in Q2 2026, selling an estimated $1.6K and leaving 13,992 shares worth $5.97K. The position accounts for ﹤0.01% of the portfolio, ranked #511.

Pekin Hardy Strauss first reported a position in HRTX in Q4 2019 and has held it in 23 quarters since. The position peaked at $12.1M in Q2 2021. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Pekin Hardy Strauss held 13,992 shares of Heron Therapeutics worth $5.97K as of Q2 2026.
  • Pekin Hardy Strauss sold 2,000 Heron Therapeutics shares in Q2 2026, an estimated $1.6K.
  • Heron Therapeutics made up ﹤0.01% of Pekin Hardy Strauss's portfolio in Q2 2026, its #511 holding.
  • Pekin Hardy Strauss first reported a position in Heron Therapeutics in Q4 2019 and has held it in 23 quarters since.
  • Pekin Hardy Strauss's Heron Therapeutics position peaked at $12.1M in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.